New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola

Deadly viruses such as Ebola are the target of Phelix Therapeutics, the newest resident of the University City Science Center’s Port business incubator at 3711 Market Street in Philadelphia.

With a $4.5 million Phase 2 SBIR grant from the National Institutes of Health in hand, Phelix Therapeutics is focused on therapies for unmet medical needs while EpiSmart is developing nutritional supplements. The company is developing first-in-class protease inhibitors based on a technology platform inspired by human biology. This platform mimics natural structures, allowing attack on protease enzymes that are involved in a range of diseases. Initial targets include antiviral therapies for SARS, MERS and Ebola, and future platform expansions are planned to address cardiac and brain disorders.

Click here to read the full press release.


©2017 PACT All Rights Reserved